AT HOME MINI-LAB MONITORING MULTIPLE BIOMARKERS FOR WOMEN’S HEALTH
Unravel Health was founded to address a critical gap in comprehensive support for women’s health by recognising that hormonal conditions affect 3.1 billion women worldwide and that traditional blood test diagnostics inadequately capture the complexity of hormonal fluctuations that are crucial to understanding women’s bodies.
With the licence assigned and exclusive IP, the Unravel team has developed a non-invasive, at-home device that uses saliva to continuously monitor up to 16 biomarkers in real-time.
Unravel’s product provides women and clinicians with actionable insights, supporting individualised healthcare decisions. Without this data, these conditions are diagnosed primarily using human judgement, resulting in delays in diagnosis and trial-error treatment.
contact: innovation@glasgow.ac.uk
THE TEAM
The female founders contribute a valuable combination of commercial, product, strategy, medicine and biomedical engineering expertise – with specialist backgrounds in AI-driven disease prediction. It is further strengthened by scientific inventors and advisors at the University of Glasgow with expertise in biosensor technology from the James Watt school of Engineering.
MEDTECH INNOVATION FUND SUPPORT
Funds support a critical step in demonstrating the flexibility and potential of the device and its adaptability to a range of medical conditions. The funding also contributes to activities associated with the development of a novel method to measure oestradiol, a pivotal advancement in hormone monitoring technology.
Unravel Health is well positioned to penetrate diverse markets. The direct-to-consumer market empowers women to take charge of their health. The business-to-business market connects with pharmaceutical companies and clinics to enhance personalised treatment options. The business-to-business-to-consumer market seeks to reach customers through strategic partnerships.
FINAL OVERVIEW
Unravel Health is preparing to ensure the Company is manufacture ready. The commercial roadmap focuses on securing lab space to expand biomarker profiles and adopt a multi-omics approach for conditions like perimenopause, migraines, and Polycystic Ovary Syndrome (PCOS). The team is set to refine its pharmaceutical strategy and solidify B2B partnerships.
More information: www.unravel.health